Orbcel-C is under clinical development by Orbsen Therapeutics and currently in Phase II for Primary Sclerosing Cholangitis. According to GlobalData, Phase II drugs for Primary Sclerosing Cholangitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Orbcel-C LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Orbcel-C overview
Stem cell therapy is under development for the treatment of primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), rheumatoid Arthritis, lupus Nephritis, crohn''s Disease and acute respiratory distress syndrome (ARDS) caused by COVID-19. The therapeutic candidate constitutes pure and defined mesenchymal stromal cells (MSCs) isolated from adult bone marrow. It is administered through intravenous drip and intravenous infusion. It is based on ORB1 technology.
See Also:
Orbsen Therapeutics overview
Orbsen Therapeutics is a regenerative medicine company focused on developing stromal cell treatments to address some of most challenging diseases. Orbsen Therapeutics is headquartered in Galway, Ireland.
For a complete picture of Orbcel-C’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
